Century Therapeutics Company Insiders

IPSC Stock  USD 1.30  0.09  7.44%   
Century Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Century Therapeutics suggests that all insiders are panicking. Century Therapeutics employs about 152 people. The company is managed by 17 executives with a total tenure of roughly 355 years, averaging almost 20.0 years of service per executive, having 8.94 employees per reported executive.

Century Therapeutics' Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-11-04Douglas CarrDisposed 283 @ 1.23View
2024-08-05Douglas CarrDisposed 289 @ 1.83View
2024-07-26Gregory RussottiDisposed 586 @ 2.5View
2024-07-23Gregory RussottiDisposed 200 @ 2.5View
2024-06-20Gregory RussottiDisposed 5000 @ 2.84View
2024-06-05Gregory RussottiDisposed 5000 @ 3View
2024-05-06Gregory RussottiDisposed 5000 @ 3.12View
2024-05-03Douglas CarrDisposed 257 @ 3.11View
2024-04-22Gregory RussottiDisposed 5000 @ 3.1View
2024-03-07Adrienne FaridDisposed 22831 @ 5.14View
2024-02-05Douglas CarrDisposed 643 @ 3.84View
Monitoring Century Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Century Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For information on how to trade Century Stock refer to our How to Trade Century Stock guide.

Century Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.209) % which means that it has lost $0.209 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6261) %, meaning that it created substantial loss on money invested by shareholders. Century Therapeutics' management efficiency ratios could be used to measure how well Century Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.4. In addition to that, Return On Capital Employed is expected to decline to -0.45. At present, Century Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 195.3 M, whereas Total Assets are forecasted to decline to about 352.6 M.
The current year's Common Stock Shares Outstanding is expected to grow to about 62 M, whereas Net Loss is forecasted to decline to (158.1 M).

Century Therapeutics Workforce Comparison

Century Therapeutics is rated second overall in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 651. Century Therapeutics totals roughly 152 in number of employees claiming about 23% of equities under Health Care industry.

Century Therapeutics Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Century Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Century Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Century Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Century Therapeutics Notable Stakeholders

A Century Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Century Therapeutics often face trade-offs trying to please all of them. Century Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Century Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
PharmD MBACEO DirectorProfile
Hyam MDPresident DevelopmentProfile
Adrienne FaridCOO DevelopmentProfile
Katja BuhrerHead SVPProfile
Michael DiemChief OfficerProfile
Morgan ConnChief OfficerProfile
Michael NasoSenior EngineeringProfile
Nick MDSenior DevelopmentProfile
Kenneth JDHead ComplianceProfile
Chad CowanChief OfficerProfile
Shane WilliamsChief OfficerProfile
Gregory RussottiChief OfficerProfile
Douglas CPASenior SecretaryProfile
Mark WalletHead VPProfile
Luis BorgesChief OfficerProfile
Michael MDChief OfficerProfile
Osvaldo FloresCEO PresProfile

About Century Therapeutics Management Performance

The success or failure of an entity such as Century Therapeutics often depends on how effective the management is. Century Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Century management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Century management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.38)(0.40)
Return On Capital Employed(0.43)(0.45)
Return On Assets(0.38)(0.40)
Return On Equity(0.74)(0.70)
Please note, the presentation of Century Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Century Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Century Therapeutics' management manipulating its earnings.

Century Therapeutics Workforce Analysis

Traditionally, organizations such as Century Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Century Therapeutics within its industry.

Century Therapeutics Manpower Efficiency

Return on Century Therapeutics Manpower

Revenue Per Employee14.7K
Revenue Per Executive131.5K
Net Loss Per Employee899.2K
Net Loss Per Executive8M
Working Capital Per Employee1M
Working Capital Per Executive9.4M

Complementary Tools for Century Stock analysis

When running Century Therapeutics' price analysis, check to measure Century Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Century Therapeutics is operating at the current time. Most of Century Therapeutics' value examination focuses on studying past and present price action to predict the probability of Century Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Century Therapeutics' price. Additionally, you may evaluate how the addition of Century Therapeutics to your portfolios can decrease your overall portfolio volatility.
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes